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Abstract 
Most tumours exhibit a high rate of glycolysis and predominantly produce energy by lactic 
acid fermentation. To maintain energy production and prevent toxicity, the lactate 
generated needs to be rapidly transported out of the cell. This is achieved by 
monocarboxylate transporters (MCTs), which therefore play an essential role in cancer 
metabolism and development.  
In vivo experiments were performed on 8 male Fisher F344 rats bearing a subcutaneous 
mammary carcinoma after injection of hyperpolarised [1-13C]pyruvate. A Gd(III)DO3A 
complex that binds to pyruvate and its metabolites was used to efficiently destroy the 
extracellular magnetisation after hyperpolarised lactate had been formed. Moreover, a pulse 
sequence including a frequency selective saturation pulse was designed so that the pyruvate 
magnetisation could be destroyed to exclude effects arising from further conversion. Given 
this preparation, metabolite transport out of the cell manifested as additional decay and 
apparent cell membrane transporter rates could thus be obtained using a reference 
measurement without a relaxation agent. In addition to slice-selective spectra, spatially 
resolved maps of apparent membrane transporter activity were acquired using a single-shot 
spiral gradient readout. 
A considerable increase in decay rate was detected for lactate, indicating rapid transport out 
of the cell. The alanine signal was unaltered which corresponds to a slower efflux rate. 
This technique could allow for better understanding of tumour metabolism and progression; 
and enable treatment response measurements for MCT-targeted cancer therapies. 













In contrast to normal cells, most cancer cells exhibit a high rate of glycolysis and 
predominantly produce energy by fermenting the generated pyruvate to lactate even in the 
presence of oxygen (1,2). This phenomenon, also called the Warburg effect, is the 
foundation for FDG PET examinations routinely used in clinical practice for diagnosis and 
treatment response monitoring in cancer patients. 
To maintain energy production and prevent toxicity, the generated lactate needs to be 
rapidly transported out of the cell. Pyruvate and lactate cannot cross the cell membrane by 
free diffusion due to their electric charge but their transport is catalysed by proton-linked 
monocarboxylate transporters (MCTs) (3). These transporter proteins are driven solely by 
the concentration gradients of the target molecule and surrounding protons, thereby also 
contributing to regulation of intra- and extracellular pH. 
Excessive lactate production and secretion are linked to many crucial steps in the progress of 
cancer: High levels of lactate in tumours are related to increased metastases and cancer cell 
resistance to radiotherapy (4-6) as well as to significantly lower overall survival rates of 
patients (7-9). Studies indicate that exogeneous lactate stimulates tumour angiogenesis, 
growth and metastasation (10-14). Moreover, high extracellular lactate concentrations were 
found to reduce the immune response to cancer cells by compromising the metabolism of 
immune cells (15-17). There is also a symbiotic relationship between cancer cells which 
release lactate as a waste product and other cancer cells which use it to fuel their energy 
production. Overall, MCTs play an essential role in cancer metabolism and development (18-
20). Therefore, a deeper understanding of MCT activity in tumours is highly desired and is 
currently the subject of intense research. 
As MCTs occupy a key position in the energy production of cancer cells, they also represent a 
promising target for new cancer therapies (21). For example, α-cyano-4-hydroxycinnamic 
acid, a drug that inhibits lactate transport in mammalian cells, was shown to reduce growth 
and induce necrosis in cancer cells by restricting lactate efflux thus impairing glycolytic 
energy production (22-25). 
Recently, dynamic nuclear polarisation (DNP) with subsequent dissolution (26) has enabled 
monitoring of uptake and metabolism of endogenous biomarkers by nuclear magnetic 
resonance methods (27-29). Dissolution DNP can achieve a signal increase of 10.000-fold or 
more for a pyruvate solution which can be used to study pyruvate-to-lactate conversion in 
tumours (30-33). However, the measured lactate signal not only reflects enzymatic 
conversion but is also affected by various other parameters such as perfusion, cell 
membrane transport, intra- and extracellular pool sizes and polarisation decay. Various 
approaches have been introduced to disentangle this complex interplay of biological 
processes such as direct quantification of inflow and outflow in bioreactors (34,35), using 
saturation and inversion transfer methods to quantify the label exchange between substrate 
and metabolite pools (36), injecting hyperpolarised alanine to determine intracellular 
pyruvate and lactate levels (37), using commercial relaxation agents that partially destroy 
extracellular magnetisation to measure altered conversion rates (38), and exploiting 
different T2 relaxation (39,40) or using diffusion gradients (41-45) to distinguish different 
microenvironments. However, these methods suffer from serious drawbacks involving 
challenges for in vivo applicability, lack of sensitivity, or ambiguity of results. Currently, a 
method for directly measuring MCT activity in vivo is not available. 
Here, we use a Gd(III)DO3A complex (46) that binds to pyruvate and its metabolites to 
efficiently destroy extracellular magnetisation after hyperpolarised lactate has been formed. 
Both slice-selective spectroscopic and imaging data were acquired in rats with a 
subcutaneous mammary carcinoma. In combination with a newly developed pulse sequence 
that saturates pyruvate magnetisation, we measured considerably increased lactate signal 
relaxation in the presence of GdDO3A which indicated high rates of lactate efflux from the 
tumour cells.  
Theory 
GdDO3A 
The idea of quenching the extracellular biomarker hyperpolarisation has been reported 
earlier (38,47); however, commercially available relaxation agents can only provide limited 
relaxation since they rely solely on outer-sphere interaction with the hyperpolarised 
molecule. In this study, we found that much higher efficiency in destroying the 
hyperpolarisation could be achieved using a coordinatively unsaturated Gd(III)DO3A complex 
(gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid). The heptadentate ligand 
leaves two vacancies in the inner coordination sphere of the Gd(III) ions that can be 
occupied by donor atoms from pyruvate or its metabolites. For several α-hydroxy-
carboxylates such as lactate, the formation of a stable ternary adduct has been observed 
(46) as shown in Figure 1. More information about this Gadolinium-chelate and its properties 
can be found in (46,48). Therefore, it is expected that GdDO3A will provide increased 
relaxation compared to coordinatively saturated complexes such as Gd(HP-DO3A) or 
Gd(BMADTPA) for these compounds. Due to the size of the complex, it will remain outside of 
the cell and can therefore be used to specifically quench extracellular magnetisation. 
In vivo pyruvate signal kinetics 
After injection, the hyperpolarised pyruvate arrives at the tumour site where it is taken up 
by the cancer cells via MCTs. Inside the cell, pyruvate is metabolised mainly to lactate by 
lactate dehydrogenase (LDH) and to alanine by alanine transaminase (ALT). The lactate 
generated is then exported to the extracellular space again by MCTs. To deduce the 
transporter activity, pyruvate signal kinetics need to be described by a multicompartment 
model considering intra- and extracellular signal portions. Assuming constant conversion and 
transporter rates, and neglecting back reaction and back transport, this will result in an 
intricate set of coupled differential equations: 
 𝑑
𝑑𝑡
𝑃𝑒𝑥𝑡 =  −𝑅1,𝑒𝑥𝑡𝑃𝑒𝑥𝑡 − 𝑘𝑃,𝑒𝑥𝑡  →𝑖𝑛𝑡𝑃𝑒𝑥𝑡 + 𝑟𝑖𝑓    (1) 
𝑑
𝑑𝑡
𝑃𝑖𝑛𝑡 =  −𝑅1,𝑖𝑛𝑡𝑃𝑖𝑛𝑡 + 𝑘𝑃,𝑒𝑥𝑡  →𝑖𝑛𝑡𝑃𝑒𝑥𝑡 − 𝑘𝑃→𝐿𝑃𝑖𝑛𝑡 − 𝑘𝑃→𝐴𝑃𝑖𝑛𝑡    (2) 
𝑑
𝑑𝑡
𝐿𝑒𝑥𝑡 = − 𝑅1,𝑒𝑥𝑡 𝐿𝑒𝑥𝑡 + 𝑘𝐿,𝑖𝑛𝑡→𝑒𝑥𝑡 𝐿𝑖𝑛𝑡    (3) 
𝑑
𝑑𝑡
𝐿𝑖𝑛𝑡 = − 𝑅1,𝑖𝑛𝑡 𝐿𝑖𝑛𝑡 + 𝑘𝑃→𝐿𝑃𝑖𝑛𝑡 − 𝑘𝐿,𝑖𝑛𝑡→𝑒𝑥𝑡 𝐿𝑖𝑛𝑡    (4) 
 
where P and L are the longitudinal pyruvate and lactate magnetisations, 𝑘𝑃→𝐿  and 𝑘𝑃→𝐴  are 
the apparent conversion rates for pyruvate-to-lactate and pyruvate-to-alanine conversion, 
𝑘𝑃,𝑒𝑥𝑡→𝑖𝑛𝑡  and 𝑘𝐿,𝑖𝑛𝑡→𝑒𝑥𝑡  are the apparent rates for cell membrane transport of pyruvate into 
and of lactate out of the cell, 𝑟𝑖𝑓  is the net pyruvate inflow rate, 𝑅1 is the spin-lattice 
relaxation rate and the indices ext and int denote the extra- and intracellular compartments, 
respectively. 
A standard FID signal does not contain any information on compartmentalisation and is the 
total of intra- and extracellular components. To crush the extracellular magnetisation, 
GdDO3A can be injected when lactate is formed and the results of this measurement can be 
compared to those of an acquisition without the relaxation agent. However, the ongoing 
inflow, uptake and conversion of pyruvate results in a different lactate signal modulation 
since pyruvate will also be crushed when GdDO3A is present. Furthermore, the lactate signal 
in the measurement with GdDO3A can still be modulated due to the conversion of 
intracellular pyruvate and label exchange from alanine over pyruvate to lactate. To remove 
these effects, a frequency selective saturation pulse on pyruvate can be used to quench the 
pyruvate magnetisation in both measurements, leaving only the magnetisation of the 
metabolites. Then, the lactate magnetisation can be described by two simplified coupled 
differential equations for extra- and intracellular magnetisation: 
𝑑
𝑑𝑡
𝐿𝑒𝑥𝑡 = − 𝑅1,𝑒𝑥𝑡 𝐿𝑒𝑥𝑡 + 𝑘𝐿,𝑖𝑛𝑡→𝑒𝑥𝑡 𝐿𝑖𝑛𝑡    (5) 
𝑑
𝑑𝑡
𝐿𝑖𝑛𝑡 = − 𝑅1,𝑖𝑛𝑡 𝐿𝑖𝑛𝑡 − 𝑘𝐿,𝑖𝑛𝑡→𝑒𝑥𝑡 𝐿𝑖𝑛𝑡    (6) 
where, for the measurement with GdDO3A, R1,ext is time-dependent due to the inflowing 
contrast agent. 
When GdDO3A is injected in high concentrations and a waiting time is implemented 
between contrast agent injection and data acquisition, a high extracellular concentration of 
GdDO3A can be assumed. Therefore, the lactate transported to the extracellular 
compartment will be crushed almost immediately and the signal equation simplifies again to  
𝑑
𝑑𝑡
𝐿𝑖𝑛𝑡 = − 𝑅1,𝑖𝑛𝑡 𝐿𝑖𝑛𝑡 − 𝑘𝐿,𝑖𝑛𝑡→𝑒𝑥𝑡 𝐿𝑖𝑛𝑡    (7) 
The apparent membrane transporter rate can then be calculated straight forward as the 
difference in the measured decay rates between the acquisition with and without added 
GdDO3A: 
𝑘𝐿,𝑖𝑛𝑡→𝑒𝑥𝑡 = 𝑅𝐿,𝑒𝑓𝑓 ,𝐺𝑑 − 𝑅𝐿,𝑒𝑓𝑓    (8) 
where 𝑅𝐿,𝑒𝑓𝑓 ,𝐺𝑑  denotes the effective relaxation rate of lactate with added GdDO3A and 
𝑅𝐿,𝑒𝑓𝑓  the effective relaxation rate of lactate without GdDO3A. The behaviour of alanine 
magnetisation is analogous to that of lactate magnetisation. Please see also Figure 2 for a 
graphical illustration. 
Materials and Methods 
GdDO3A relaxation properties 
The longitudinal relaxation times of the 13C label of the three substrates [1-13C] pyruvate, 
[1-13C] lactate and [1-13C] alanine with different ratios of GdDO3A were quantified in serum 
(FBS). The concentration of metabolites and of the paramagnetic contrast agent was similar 
to the one obtained in in vivo experiments (5 mM pyruvate concentration, assuming a 1ml 
injection of 80 mM pyruvate is diluted in 15 ml of rat blood). The effect of the GdDO3A 
complex was compared with that of the coordinatively saturated Gd(HP-DO3A) (trade name: 
ProHance). These measurements were performed at 14T (Bruker Avance 600MHz 
spectrometer), using the inversion recovery pulse sequence. 
Hyperpolarisation 
[1-13C]pyruvic acid doped with 15 mM trityl OX063 radical and 1 mM Dotarem was 
polarised in a HyperSense DNP polariser (Oxford Instruments, Abingdon, UK). After 1 h, the 
frozen sample was rapidly dissolved by flushing with a hot aqueous solution containing 80 
mM Trizma buffer, 80 mM NaOH, and 0.1 g/L Na-EDTA, resulting in an 80 mM pyruvate 
solution with physiological pH, osmolarity, and temperature. The liquid-state polarisation 
was approximately 25%. 
Scanner setup 
In vivo experiments were performed on a clinical 3T HDx scanner (GE Healthcare, 
Milwaukee, WI) with maximum gradient amplitude of 40 mT/m and maximum slew rate of 
150 T/m/s. A dual-tuned 13C-1H birdcage volume coil (diameter: 8 cm) was used for radio-
frequency transmission and reception (49). 
Animal handling 
The proposed protocol was tested in 8 male Fisher F344 rats (Charles River) with a 
subcutaneous Mat BIII tumour in the neck region. Mat BIII syngeneic cells from rat mammary 
adenocarcinoma were maintained in McCoy's 5a Medium Modified (catalogue no. 30-2007; 
ATCC, Manassas, MA) supplemented with 10% FCS. Cells were kept in a humidified 
atmosphere at 5% CO2 and 37°C. At the time of implantation they were harvested and 
washed twice; approximately 106 cells were implanted subcutaneously into the shoulder in 
serum-free medium. Tumours reached a size of ~1.5 cm within 10 days after implantation. 
During the experiment, the animals were anaesthetised with 1–3% isoflurane gas inhalation. 
They were monitored using ECG and for breathing, oxygen saturation and temperature, and 
were kept warm on a heating pad with circulating warm water. Then, 1 ml of dissolved 80 
mM hyperpolarised pyruvate solution was injected into the tail vein. The animal study was 
approved by the local governmental committee for animal protection and welfare 
(Tierschutzbehörde, Regierung von Oberbayern). 
Pulse sequence design 
A 2D spectral-spatial RF pulse to selectively excite pyruvate or its metabolites was designed 
by direct inversion of the excitation matrix (50,51). The pulse consisted of 18 lobes with total 
pulse length of 22.4 ms and used flyback-gradients to increase robustness against gradient 
errors. 
For spatial encoding, a single-shot spiral gradient readout (FOV 8 cm; resolution 24×24 
pixels; maximum gradient amplitude 13 mT/m; maximum gradient slew rate 46 T/m/s) was 
created using the variable density spiral generation script by Brian Hargreaves (52). 
A spectroscopic acquisition sequence was implemented using the spectral-spatial RF pulse. 
First, the pulse was executed on the pyruvate frequency without slice selection using a flip 
angle of 90° and a subsequent spoiler gradient. Then, lactate and alanine signal was acquired 
slice-selectively with a flip angle of 6° in subsequent excitations with a repetition time of 100 
ms so that a full set of metabolite signals with preceding pyruvate saturation was obtained 
every 300 ms. The readout time was 51.2 ms with a readout bandwidth of 5 kHz and a total 
of 256 points. 
For imaging, the repetition time was increased to 200 ms and the pulse sequence was 
modified to include three excitations using the pyruvate saturation pulse without slice 
selection followed by slice-selective excitations with 20° on the lactate and alanine 
frequency. The single-shot spiral readout gradient was used for spatial encoding. A full set of 
metabolite images with preceding pyruvate saturation could be obtained every second. The 
readout time was 65.5 ms with a readout bandwidth of 62.5 kHz and a total of 4096 points. 
For a schematic drawing of the individual pulse sequences, please see Figure 3. 
Measurement protocol 
For each animal, two separate injections were performed 1 h apart: the first without and the 
second with administration of 0.5 ml of a GdDO3A solution 16 s after the pyruvate injection 
at the supposed plateau of the lactate signal. The relative amount of GdDO3A compared to 
pyruvate was chosen to be 1:5 for 7 rats and 1:1 for one rat to test concentration effects. 
After 20 s, the pulse sequence described above was started. Spectroscopic data were 
acquired for 4 rats and imaging data for another 4 rats in a 14-18 mm slice including the 
tumour. In the time between the two injections, fast-recovery fast spin-echo (FRFSE) 1H 
images with slice thickness of 3 mm were acquired in the centre of the 13C tumour slice to 
provide anatomical reference. 
DCE study 
The time dependence of the concentration of the paramagnetic complex in the tumour 
tissue during the first few seconds after the injection has been separately studied at a 7T 
small animal scanner (Agilent Technologies) using four rats bearing a Mat BIII tumour. A time 
resolved imaging of contrast kinetics (TRICKS) sequence was used to acquire T1-weighted 
proton images every 2.67 s (resolution 128×128 pixels, FOV 8 cm). The injection of GdDO3A 
contrast agent followed the same protocol as used for the hyperpolarised acquisitions. 
Relaxation rates for extended modelling were calculated based on the in vitro results by 
assuming a homogeneous distribution of contrast agent in the rat blood volume. 
Immunohistochemistry 
Separately implanted subcutaneous MAT BIII tumours were fixed in 4% neutral-buffered 
formalin, routinely embedded in paraffin and cut into 2µm thick consecutive slices. 
Immunohistochemistry to detect MCT 1 (Merck-Millipore AB1286-I) and MCT 4 (Santa Cruz 
Biotechnologies sc-50329) expression was performed after heat-mediated antigen retrieval 
for 20 minutes in citrate buffer (pH6) with goat anti-chicken (MCT1, medac diagnostics 16-
24-06) or goat anti-rabbit (MCT4, medac diagnostics 71-00-30) secondary antibodies and a 
strepatvidine-peroxidase detection system (medac diagnostics 71-00-38) visualized by Dab 
(medac diagnostics BS04). 
Reconstruction 
A 15 Hz Gaussian filter was applied along the readout dimension to both spectroscopy and 
imaging data. Fast Fourier transform (FFT) was applied to the spectroscopy data to 
reconstruct spectra. Spiral imaging data were phase corrected along the readout for the 
resonance frequency of the specific metabolite. Subsequently, a non-uniform fast Fourier 
transform (NUFFT) (53) was used to reconstruct spiral data onto a Cartesian grid.  
Since in vivo acquisitions of hyperpolarised biomarkers typically suffer from low SNR 
compared to standard proton acquisitions, it is important to avoid the Rician bias (54) from 
absolute value images or spectra when fitting the decay rates. Thus, the spectra were phase 
corrected and the peak value of the real valued spectrum was used for further evaluation.  In 
this special case, the images feature the same structures with decreasing SNR; thus the 
mean phase from the first few images with sufficient SNR (where the noise is nearly 
Gaussian distributed) was taken to correct the whole image series. For the lactate imaging 
acquisitions, regions of interest (ROIs) were drawn manually to calculate the mean tumour 
signal. As alanine is not specific to the tumour tissue, ROIs were generated by taking each 
image voxel with a signal >70% of the maximum signal within the first image. 
A monoexponential fit was applied to the decay curves of the metabolites starting 3 s after 
beginning the acquisition when pyruvate was completely saturated and the signal dynamics 
had reached equilibrium. Apparent cell transporter activity rates were calculated according 
to equation (8). Furthermore, spatially resolved maps of the apparent lactate MCT 
transporter rate were obtained by applying the fit on each voxel with a signal > 30 % of the 
maximum signal within the first image. 
To judge the validity of the assumption that the extracellular compartment is crushed 
immediately, the spectroscopic data that had a higher time resolution were fitted from the 
start using equations (5) and (6) with the time-dependent R1 relaxation values derived from 
proton DCE measurements. 
Results 
GdDO3A relaxation properties 
The T1 values measured in vitro are reported in Table 1. Compared to the coordinatively 
saturated Gd(HP-DO3A) complex (trade name: ProHance), GdDO3A could achieve an 
approximately 10-fold reduction of T1 relaxation times for lactate and alanine in serum. It 
must be mentioned that the in vitro measurements were carried out at 14T, while the in vivo 
experiments are made at 3T. However, while the T1 of the 13C carboxylate metabolites’ 
signal is strongly dependent on the magnetic field strength, the paramagnetic contribution 
of the Gd-DO3A to the relaxation rate is the same in the two different fields.  
DCE study 
Consistent with literature reports of commercial Gd-complexes, it was found that 
immediately after the injection of the GdDO3A contrast agent in the vein, its concentration 
in the tumour area increases in the first 20 seconds, after which it is slowly washed out. The 
time dependent relaxation rates (R1) of the metabolites were calculated and are shown in 
Figure 4. The measurements confirm that a sufficient concentration of GdDO3A is reached 
during the hyperpolarised 13C acquisition. Furthermore, from previous reports of contrast 
agents of similar molecular size (55), it is known that the bulk part of the contrast agent is 
directly excreted into the interstitial space. The signal time evolution is shown in 
Supplementary Figure 1, and the derived relaxation curves are given in Supplementary 
Figure 2. 
Immunohistochemistry 
Tumours of subcutaneous Mat BIII syngrafts show a strong membranous MCT1 and a 
moderate membraneous MCT4 expression (see Supplementary Figures 3 and 4). 
In vivo hyperpolarisation experiments 
The fitted apparent efflux rates of lactate (𝑘𝐿,𝑖𝑛𝑡→𝑒𝑥𝑡 ) and alanine (𝑘𝐴,𝑖𝑛𝑡→𝑒𝑥𝑡 ) can be found in 
table 2. The mean value of 𝑘𝐿,𝑖𝑛𝑡→𝑒𝑥𝑡  from the spectroscopy acquisitions (rat 1-3) was 0.20 ± 
0.05 s-1, the mean value from the imaging acquisitions (rat 5-8) 0.18 ± 0.03 s-1. For alanine, 
no significant difference in decay rates was found within the noise level (spectroscopy rat 1-
3: 0.01 ± 0.01 s-1, imaging rat 5-8: 0.02 ± 0.02 s-1). Rat 4 with a pyruvate to Gd ratio of 1:1 
shows a slightly elevated apparent export rate for lactate (0.31 s-1) whereas the alanine 
signal is unchanged again. To verify the effectiveness of the pyruvate saturation pulse, the 
pyruvate spectroscopy signal was analysed for the first injection without relaxation agent. 
The remaining pyruvate magnetisation in the entire rat body was found to be 4% ± 5% at the 
beginning of the decay rate fit. The overlays of the 13C metabolite maps with the anatomical 
proton images confirmed that most of the lactate signal in the slice stemmed from the 
tumour, whereas alanine was distributed mostly in the surrounding tissue (data not shown). 
The SNR of the lactate images was sufficient to derive spatially resolved maps of 𝑘𝐿,𝑖𝑛𝑡→𝑒𝑥𝑡  
which showed homogeneous apparent transporter activity within the tumour area. 
Exemplary datasets for spectroscopy and imaging are presented in Figures 5 and 6, 
respectively.  
The extended model including extra- and intracellular compartments with a time-dependent 
extracellular relaxation rate yielded slightly increased values for 𝑘𝐿,𝑖𝑛𝑡→𝑒𝑥𝑡  as compared to 
the simple decay rate fitting model (16% increase on average). For 𝑘𝐴,𝑖𝑛𝑡→𝑒𝑥𝑡 , the results 
were unchanged. 
Discussion and Conclusions 
From relaxation rate measurements carried out in vitro (in plasma) it is clear that the Gd-
DO3A complex allows extremely fast relaxation of the signal of hyperpolarised metabolites, 
much faster than using other commercial Gd(III) contrast agents, even when the 
concentration of both the paramagnetic complex and the metabolite is lower than 1 mM. 
Judging from the in vitro results, GdDO3A is therefore a superior candidate to create 
contrast between intra- and extracellular magnetisation for hyperpolarised pyruvate 
experiments. Furthermore, in a separate DCE study we found that the GdDO3A 
concentration rises quickly in the tumour during the hyperpolarised 13C acquisition. 
However, a quantitative measurement as well as a comparison with commercially available 
contrast agents in a future in vivo study might be advisable.   
In vivo data from a preliminary study with GdDO3A conducted in healthy rats are shown in 
Figure 4. Significant alteration of signal kinetics can be observed for both lactate and alanine, 
which could be due to efflux from the cells or loss of hyperpolarised flux from pyruvate. 
Using standard NMR methods, this dilemma cannot be resolved as there are too many 
unknowns to fit the curves to the required 6 compartment model. Even if more information 
was available, the fit would most likely be error-prone due to the typically low SNR regime of 
hyperpolarised acquisitions. The proposed method elegantly reduces the problem to simply 
fitting the decay rates by completely eliminating the influence of pyruvate conversion. 
We found a significant difference of lactate decay in the presence of GdDO3A, which 
indicates considerable lactate efflux in the tumour tissue. This is also consistent with the 
immunohistochemical analysis, which shows a strong membranous MCT1 expression and a 
moderate membranous MCT4 expression. These are two of the most important transporters 
responsible for lactate transport. While MCT4 is the transporter believed to be mainly 
responsible for the export of glycolysis-derived lactate occurring in hypoxic tumours (56,57), 
there is evidence that under certain circumstances, also MCT1 can become a major pathway 
for lactate efflux (13). 
For alanine, no significant difference in decay rates could be found, suggesting that alanine 
excretion occurs on a much slower time scale. This is consistent with our assumptions, since 
alanine is an amino acid and not transported by MCTs but by a range of other transporter 
systems that require the co-transport of other amino acids (58). As a non-essential amino-
acid, alanine mostly serves as an exchange substrate for the uptake of essential amino acids 
in mammalian cells. We therefore expected its efflux rate to be at least one order of 
magnitude lower than the values found for lactate (59). These results confirm the sensitivity 
of the method for detecting lactate transport out of the cell. 
The results obtained from the extended model are slightly higher than those for the simple 
model which assumes instantaneous quenching of the extracellular compartment. This was 
expected, since a lower relaxation rate in the extracellular compartment translates to higher 
actual transporter rates. This is also indicated in rat 3 where a higher GdDO3A concentration 
was used, and the values from both models were similar. Therefore, results of the extended 
model confirm that the assumption of immediate relaxation in the extracellular 
compartment is practicable and will introduce only little error regarding influence of the 
inflowing contrast agent. This simple model also avoids the necessity of acquiring DCE 
proton data. To improve accuracy, future studies should use a higher concentration of 
GdDO3A if possible.  
As there is no gold standard to compare the results to, the limitations of the described 
technique must be thoroughly evaluated in further studies. In principle, the same challenges 
arise as for the apparent conversion rate constants describing the metabolic conversion. As a 
result of relaxation, the hyperpolarised in vivo signal cannot be directly related to absolute 
molecule concentrations. Also, the measurements may be complicated by underlying 
biological processes such as perfusion, label exchange and other influences. One important 
factor is the perfusion and accumulation of the GdDO3A agent; results may be biased by 
insufficient concentration or slow inflow into the target tissue. This is indicated by rat 4, 
which received a higher concentration of the GdDO3A compound, resulting in elevated 
values of the decay. If quantitative proton T1 maps and 13C data can be acquired in the 
same scan, as demonstrated in (38), the obtained concentration of GdDO3A may be used to 
improve accuracy and provide more information on the dynamics during the GdDO3A bolus. 
To increase the relaxation weighting, a higher concentration of GdDO3A should be used in 
future examinations if possible. Moreover, a real-time bolus tracking approach could be 
adapted to automatically detect the optimal time point for starting the acquisition at the 
peak of the lactate curve (60). Furthermore, the influence of the intra- and extracellular pool 
sizes needs to be investigated. If there is a large extracellular pool, most of the signal may 
stem from the decay of this pool. Also, it is currently not possible to distinguish between net 
transport and label exchange between the intra- and extracellular pool. In (44), diffusion-
sensitive measurements imply that the vascular fraction of pyruvate and lactate is rather 
small in prostate tumours. Regarding this issue, the pulse sequence could be modified to 
acquire spin echoes. This may allow better investigation of the extra- and intracellular 
compartment sizes of the metabolite signal due to varying T2 relaxation time with and 
without GdDO3A administration. Another interesting approach could be to incorporate the 
GdDO3A complex into a liposome structure to target only intravascular hyperpolarisation. 
This may provide valuable complementary information on the distribution of metabolites 
between vascular, interstitial, and intracellular spaces. For these reasons, tumour models 
with a different rate of lactate export have to be studied in order to determine whether the 
contrast provided by the proposed method is sufficient to distinguish between different 
tumour types or disease states. 
In conclusion, we present a method that potentially allows direct measurement of cell 
membrane transport in vivo using hyperpolarised biomarkers. Significantly increased decay 
rates were found for lactate in rats with mammary carcinoma in the presence of GdDO3A, 
indicating rapid transport out of the cell. In addition to slice-selective spectra, spatially 
resolved maps of apparent membrane transporter activity could be obtained. This technique 
could allow for better understanding of tumour metabolism and progression; and could 
enable treatment response measurements for MCT-targeted cancer therapies. Moreover, it 
may provide vital insights into the signal kinetics of hyperpolarised [1-13C]pyruvate 
examinations. 
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Tables 
 Pyr [5 mM] Lac [0.5 mM] Ala [0.5 mM] 
Gd-HP-DO3A [1 mM] 2200±300 ms 500±50 ms 700±20 ms 
GdDO3A [1 mM] 90±10 ms 43±5 ms 35±5 ms 
GdDO3A [0.1 mM] 800±50 ms 400±50ms 330±30 ms 
Table 1. T1 measured in serum for pyruvate, lactate and alanine in the presence of Gd-HP-
DO3A and GdDO3a. 
 






1 spectr. 1:5 0.16 ± 0.01 0.02 ± 0.01 
2 spectr 1:5 0.19 ± 0.04 0.00 ± 0.01 
3 spectr. 1:5 0.25 ± 0.04 0.01 ± 0.01 
4 spectr. 1:1 0.31 ± 0.07 0.02 ± 0.01 
5 imaging 1:5 0.15 ± 0.04 0.02 ± 0.02 
6 Imaging 1:5 0.18 ± 0.01 0.02 ± 0.02 
7 Imaging 1:5 0.16 ± 0.05 0.03 ± 0.02 
8 imaging 1:5 0.22 ± 0.03 -0.01 ± 0.03 
Table 2. Results from in vivo experiments in Fisher F344 rats bearing a subcutaneous Mat BIII 
tumour in the neck region. Given are the mode of acquisition (spectroscopy or imaging), the 
concentration ratio of GdDO3A and the apparent  cell membrane transporter activity rates 













Figure 1. Formation of a reversible ternary adduct between GdDO3A and lactate (see 
(46,48)). 
Figure 2. In vivo signal kinetics of hyperpolarised [1-13C]pyruvate in a cancer cell. Left: 
Standard NMR acquisition, intra- and extracellular compartments cannot be separated, right: 
saturation pulse destroys pyruvate magnetisation and only intracellular metabolite signals 
are left. If transported out of the cell, the metabolite magnetisation will be quenched by 
GdDO3A. Therefore, the MCT transporter activity manifests as additional decay in the 
presence of GdDO3A. 
Figure 3. Acquisition schemes for the presented substrate saturation sequence. Top row: FID 
readout without gradient; bottom row: imaging acquisition with single-shot spiral gradient 
readout. 
Figure 4. Representative dataset from a preliminary study without saturation pulse: 
Spectroscopic acquisitions of a kidney slice (slice thickness 14 mm) from a healthy rat after 
injection of hyperpolarised [1-13C]pyruvate. The plot shows the metabolic time curves 
without (blue) and with administration of GdDO3A (red) for lactate (a) and alanine (b). A 
significant difference can be observed for both metabolites, which could be due to efflux or 
loss of hyperpolarised flux from pyruvate. The proposed method with saturation pulse 
allows resolution of this issue.  
Figure 5. Representative dataset from rat 1 for spectroscopic acquisition. The plot shows 
metabolite decay without (blue) and with administration of GdDO3A (red) as well as the 
corresponding monoexponential fits (black) for lactate (a) and alanine (b). A significant 
difference in decay can be observed for lactate, indicating rapid lactate efflux. 
Figure 6. Representative dataset from rat 6 for imaging acquisition. a) FRFSE proton image 
for anatomical reference b) Lactate signal (sum of first three images) overlaid with a proton 
image c) Apparent MCT transporter map overlayed with a proton image (signal masked for > 
30% of the maximum). 
Supplementary Figures 
Figure 1. Time series of DCE measurement (zoomed in at the tumour). A time resolved 
imaging of contrast kinetics (TRICKS) sequence was used to acquire T1-weighted proton 
images every 2.67 s (resolution 128×128 pixels, FOV 8 cm). 
Figure 2. 13C relaxation rates of the carboxylate signals of  lactate (filled circles, red) and 
alanine (open circles, blue)  as a function of the time-dependent concentration of GdDO3A in 
the blood flow, after the injection of CA. These values have been derived from in vitro 
measurements of 13C relaxation rates of lactate and alanine using approximately the same 
concentration as in blood of the metabolites and the Gd complex. The time dependent 
concentration of the CA has been derived from DCE study. 
Figure 3. MCT1 immunohistochemical assay (Merck-Millipore AB1286-I), bars 50 µm. 
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